[{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion NV Reports First Patient Dosed in Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion NV to Present at Wet AMD and DME Drug Development Summit","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Publishes Data Shwoing Potential of Pan-RGD Integrin Antagonists to Improve the Treatment of Diabetic Retinopathy and Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OXURION - Positive Phase 2 Part A THR-149 Data Shared at The America Society of Retinal Specialists (ASRS) Annual Scientific Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OXURION NV - First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrations of THR-149 versus aflibercept for Treatment of Diabetic Macular Edema (DME)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Kreos Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Provides Update on Clinical Pipeline Progress","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Bank Degroof Petercam","pharmaFlowCategory":"D","amount":"$11.4 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Successfully Raises Eur >10 Million From Leading Us And European Healthcare Investors In A Private Equity Placement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$11.5 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Successfully Closes EUR >10 Million in Private Placement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces Preclinical Data on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Negma Group","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in Funding","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces Interim Analysis for KALAHARI Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Further Improves THR-149 Patent Position","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macular Edema Following Interim Analysis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Negma Group","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Funding Program Between Oxurion and Negma Ends","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas Special Opportunities LL","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","amount":"$22.4 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLC","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","amount":"$22.7 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLC","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"VIB","pharmaFlowCategory":"D","amount":"$32.4 million","upfrontCash":"$0.4 million","newsHeadline":"Oxurion Receives Upfront Payment of $400,000 Following Oncurious Asset License by VIB","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Receives Funding of EUR One Million under Atlas Special Opportunities LLC (Atlas) Funding Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Announces Key Amendments to Atlas and Kreos\/Pontifax Agreements Enabling KALAHARI Trial to Progress to Topline Results in 2023","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","amount":"$3.7 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Receives First EUR 1 Million under Amended Atlas Funding Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Oxurion"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
The financing will be used for the development of THR-149, a bicyclic peptide that selectively inhibits human plasma kallikrein, for the treatment of patients with diabetic macular edema.
The financing from the agreement will enable Oxurion to progress the Phase 2, Part B KALAHARI trial of THR-149, a potent PKal inhibitor, in Diabetic Macular Edema (DME).
The financing will be used for the development of THR-149, a bicyclic peptide that selectively inhibits human plasma kallikrein, for the treatment of patients with diabetic macular edema.
Under the agreement, VIB acquired Oxurion's preclinical oncology asset and will use the upfront in the development of THR-149, being evaluated in a Phase 2 clinical trial as a potential treatment for of diabetic macular edema.
The net proceeds will be used to fund the Phase 2, KALAHARI trial evaluating Oxurion’s THR-149, a bicyclic peptide that selectively inhibits human plasma kallikrein, for treating the up to 50% of patients with diabetic macular edema (DME).
THR-149 is a bicyclic peptide that selectively inhibits human plasma kallikrein (PKal) with an inhibition constant of 0.22 nM. THR-149 is currently being evaluated for Diabetic Macular Edema.
THR-149 is a bicyclic peptide that selectively inhibits human plasma kallikrein (PKal) with an inhibition constant of 0.22 nM. Through the inhibition of the kallikrein-kinin system (KKS), THR-149 prevents the induction of retinal vascular permeability and inflammation.
The financing will be used to progress towards finishing patient recruitment for the Phase 2, Part B KALAHARI trial evaluating Oxurion’s THR-149 for treating the up to 50% of patients with diabetic macular edema (DME).
The financing will be used to fund the Phase 2, Part B KALAHARI trial evaluating Oxurion’s THR-149, a bicyclic peptide that selectively inhibits human plasma kallikrein (PKal), for treating the patients with diabetic macular edema (DME).
THR-149 is a bicyclic peptide that selectively inhibits human plasma kallikrein (PKal) with an inhibition constant of 0.22 nM. Through the inhibition of the kallikrein-kinin system (KKS), THR-149 prevents the induction of retinal vascular permeability and inflammation.